| Course | NR 571 Complex Diagnosis and Management in Acute Care Practicum |
|---|---|
| Week | 5 |
| Paper type | Comorbidity conflict brief |
| Length | About 830 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Adult-Gerontology Acute Care NP (AGACNP) |
| Updated | October 2026 |
Free sample paper for NR 571 Week 5
Comorbidity Conflict Brief: Myasthenia Gravis Removes the Macrolide and the Fluoroquinolone From a Pneumonia Plan, and What the Doxycycline Substitute Costs and Requires
Student Name
College of Nursing, Chamberlain University
NR 571: Complex Diagnosis and Management in Acute Care Practicum
Instructor Name
Month Day, Year
Comorbidity Conflict Brief: Myasthenia Gravis Removes the Macrolide and the Fluoroquinolone From a Pneumonia Plan, and What the Doxycycline Substitute Costs and Requires
The Comorbidity and the Option It Removes
Generalized myasthenia gravis removes two antibiotic classes from this patient's pneumonia plan: the macrolides and the respiratory fluoroquinolones. Both can impair transmission at the neuromuscular junction and have been reported to precipitate worsening or crisis in myasthenia; the fluoroquinolones carry a boxed warning for this effect, and macrolides including azithromycin appear repeatedly in published reports of exacerbation (Sheikh et al., 2021). The patient's bedside breathing numbers were already falling on admission, so any drug that could deepen the weakness carries more risk than usual. Infection is itself one of the commonest triggers of myasthenic worsening (Gilhus, 2016), which means the antibiotic is being chosen at the moment the patient is least able to absorb a second insult.
The Basis for the Original Plan
For an adult admitted to a general ward with community-acquired pneumonia, the joint ATS/IDSA guideline names two strong first choices: ceftriaxone or another beta-lactam paired with a macrolide, or a respiratory fluoroquinolone given by itself (Metlay et al., 2019). Without the myasthenia, this patient would have received ceftriaxone with azithromycin.
The Altered Plan, in Full
Ceftriaxone 1 g through the vein once a day, plus doxycycline 100 mg through the vein every 12 hours, switching to oral doxycycline once a swallow assessment confirms the patient can take tablets safely. Planned length: at least five days and until the patient has been stable without fever for 48 hours, as the guideline advises. Urinary Legionella antigen sent on admission. Blood and sputum cultures sent before the first doses. Procalcitonin is not used to decide whether to start antibiotics, consistent with the guideline.
This exact pairing appears in the guideline as the fallback when neither macrolides nor fluoroquinolones can be used, though the guideline grades it conditional, resting on low-quality evidence (Metlay et al., 2019).
What Is Lost by the Substitution
The macrolide was in the original plan to cover atypical organisms, chiefly Legionella, Mycoplasma and Chlamydophila, and because the combination of a beta-lactam and a macrolide has the strongest evidence among the guideline's choices for hospitalized adults. Doxycycline covers the same organisms in the laboratory, but the clinical evidence behind it for hospitalized patients is thinner. The outcome the macrolide was chosen to protect, cure of an atypical or Legionella pneumonia without treatment failure, is therefore protected less securely. For this patient that is an accepted loss, because the alternative risks a myasthenic crisis. If the patient had severe pneumonia needing intensive care, the balance would be different, and a fluoroquinolone with close neuromuscular monitoring might be the safer choice.
Monitoring the Substitution Creates
Three things need watching because of this change, separate from the monitoring the myasthenia and the pneumonia would need anyway.
First, the Legionella urinary antigen result. If it is positive, doxycycline is no longer an adequate substitute, and the team must decide between a fluoroquinolone with intensive neuromuscular monitoring, ideally in intensive care, or another agent with infectious disease advice. The result is due within 24 hours, and the person who reads it is the admitting nurse practitioner on day 2.
Second, the response at 48 to 72 hours. A pneumonia that is not improving by then on a less-proven regimen deserves a second look at the cultures and at the choice of drug, sooner than it would on a standard regimen.
Third, the oral switch. Doxycycline tablets can lodge in the esophagus and cause ulceration if taken without enough water or while lying down, and this patient has a swallowing difficulty from the myasthenia. Oral doxycycline is started only after the swallow assessment, with at least 240 mL of water, the patient sitting upright for half an hour afterward.
How the Change Was Recorded and Shared
The pharmacist was told of the substitution and the reason, and confirmed that doxycycline needs no kidney dose adjustment at this level of function. The patient's chart now lists myasthenia gravis in the drug intolerance field with the entry: avoid macrolides, fluoroquinolones and aminoglycosides unless discussed with neurology, so that an overnight clinician or a future admitting team sees the restriction before ordering. The patient and spouse were told in plain words why the usual antibiotic was not used, and said that a previous emergency visit had once given azithromycin before anyone checked.
What This Brief Does Not Cover
It does not address the myasthenic worsening itself, which is the subject of a separate analysis, or the heart rate, the glucose or the bone medicine. It assumes the reader has the case in front of them and does not repeat the history.
References
Gilhus, N. E. (2016). Myasthenia gravis. New England Journal of Medicine, 375(26), 2570-2581. https://doi.org/10.1056/NEJMra1602678
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., Griffin, M. R., Metersky, M. L., Musher, D. M., Restrepo, M. I., & Whitney, C. G. (2019). Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine, 200(7), e45-e67. https://doi.org/10.1164/rccm.201908-1581ST
Sheikh, S., Alvi, U., Soliven, B., & Rezania, K. (2021). Drugs that induce or cause deterioration of myasthenia gravis: An update. Journal of Clinical Medicine, 10(7), Article 1537. https://doi.org/10.3390/jcm10071537
Reading the NR 571 Week 5 instructions
The Week 5 brief asks you to show how one of your patient's conditions removes an option that would otherwise be standard for another. Expect one or two pages with no history section, since the reader already knows the case. Open on the comorbidity and the option it removes, with the basis for saying so and a source. Give the altered plan in full rather than as an amendment. A short paragraph should say what is lost by the substitution, in terms of the outcome the original choice was meant to protect. Most rubrics weigh the last section heavily: the monitoring that the substitution itself creates.
How the NR 571 Week 5 example is put together
The sample states in its first paragraph that myasthenia removes two antibiotic classes, citing a review of drugs that worsen the disease and noting that infection is itself a trigger. It then gives the guideline's strong first choices for a ward patient. The altered plan names drugs, routes, length, cultures and the Legionella test in full, and notes that the guideline allows this pairing as a conditional fallback. A paragraph explains what atypical coverage is weakened. Three monitoring items follow, each created by the substitution, including safe oral doxycycline with impaired swallowing. A section records the chart entry and the patient's own story about azithromycin.
NR 571 Week 5 rubric: what full points look like
The monitoring section is where most briefs lose marks, so this sample gives it three specific items, each tied to the substitution rather than to the disease. Opening on the comorbidity and the removed option, with a source, satisfies the first criterion. An altered plan written in full scores above one written as a change to the original. Stating what is lost, in terms of the outcome at stake, shows that the trade was understood. Brevity is graded, since a brief that retells the history misreads its audience. Recording the restriction where future prescribers will see it often earns safety or communication points. A short statement of what the brief does not cover keeps it within its page limit.
NR 571 Week 5 help: mistakes that cost points
The most common NR 571 Week 5 problem is a brief that ends at the substitution with no monitoring. Another is a brief that opens with a page of history, though the reader already has the case. Some writers give the altered plan as a single line that only makes sense next to the original. Others claim the substitute is equivalent when the evidence is weaker. Many forget to record the restriction for future prescribers. If your patient's comorbidity removes a different option, send both conditions and the original plan; a brief can be written that gives the altered plan in full and the monitoring it creates. Keep the whole brief to one or two pages so a busy reader finishes it.
Get a NR 571 Week 5 example written to your instructions
Tell us the comorbidity and the option it rules out, attach the brief instructions your classroom posted, and an example of the finished document comes back inside 24-48h, free the first time. If the assignment caps the length, say so and the sample will be written to that limit.
More NR 571 papers and AGACNP samples
- NR 571 Week 1: Multimorbidity Threshold Post
- NR 571 Week 2: Myasthenia and Pneumonia Case Paper
- NR 571 Week 3: Problem List Prioritization
- NR 571 Week 4: Competing Treatment Analysis
- NR 571 Week 6: Goals of Care Record
- NR 571 Week 7: Rounds Case Brief
- NR 571 Week 8: Concurrent Problem Synthesis
- NR 570 Week 5: Progress Note Sequence
- NR 569 Week 5: Diagnostic Test Rationale
- NR 567 Week 5: ICU Sedation and Analgesia Plan
NR 571 Week 5 questions, answered
How short is a brief supposed to be?
Short enough that a reader takes it in at once, which in most sections means a page or so. The limit is part of the assignment rather than an inconvenience: cutting history and background is what forces the constraint and its consequence into view. Where a word limit is published, treat it as the specification.
Can I write the brief about a drug interaction?
Usually yes, if the assignment allows it, but the document still has to be an ordering argument rather than an interaction table. Name the option that closes, give the plan that replaces it, and say what is given up. The chemistry belongs in one line. Where your section has its own pharmacology course running, keep the depth there.
What if nothing can replace the option that is lost?
Then that is the finding and the brief says it. A document concluding that the remaining choices are all worse, and naming what each one costs, is a stronger piece of work than one that manufactures an equivalent. Rubrics on this week reward the writer who reaches an uncomfortable answer and stays with it.
Where can I find a free NR 571 Week 5 sample paper?
This page shows the full brief on how myasthenia gravis changes a pneumonia antibiotic plan, from removed options to new monitoring.
What monitoring does the substitution create in the NR 571 Week 5 brief?
The Legionella antigen result, the clinical response at 48 to 72 hours on a less-proven regimen, and safe oral doxycycline given impaired swallowing.